Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Verdinexor in Healthy Adults
NCT02431364Phase 1Terminated
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of verdinexor in influenza (5 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Treatment-emergent Adverse Events. Started May 2015; status: terminated.
02
Drugs
verdinexor
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02431364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431364.